Effect on Kidney Function Recovery Guiding Decongestion with VExUS in Patients with Cardiorenal Syndrome 1: A Randomized Control Trial [0.03%]
VExUS指导利尿撤除对1型心肾综合征患者肾脏功能恢复的影响：一项随机对照试验
J P Islas-Rodríguez,Tomas Miranda-Aquino,Gregorio Romero-González et al.
J P Islas-Rodríguez et al.
Introduction: In cardiorenal syndrome type 1 (CRS1), vascular congestion is central to the pathophysiology of heart failure and thus a key target for management. The venous evaluation by ultrasound (VExUS) system could gu...
Randomized Controlled Trial
Cardiorenal medicine. 2024;14(1):1-11. DOI:10.1159/000535641 2024
Bedside Ultrasound in the Management of Cardiorenal Syndromes: An Updated Review [0.03%]
心脏肾脏综合征综合管理的床旁超声检查：最新综述
Eduardo R Argaiz,Gregorio Romero-Gonzalez,Philippe Rola et al.
Eduardo R Argaiz et al.
Background: Cardiorenal syndromes constitute a spectrum of disorders involving heart and kidney dysfunction modulated by a complex interplay of neurohormonal, inflammatory, and hemodynamic derangements. The management of ...
QTc Interval Prolongation Is Independently Associated with FGF23 and Predicts Mortality in Predialysis Chronic Kidney Disease [0.03%]
FGF23与透析前慢性肾脏病患者的QT间期延长独立相关并可预测患者预后
Tabo Sikaneta,Natalie Ho,Antonio Bellasi et al.
Tabo Sikaneta et al.
Introduction: QTc interval prolongation is increasingly frequent as chronic kidney disease (CKD) advances and predicts death in dialysis. However, predictors and mortality risk in predialysis CKD are understudied. FGF23 i...
Observational Study
Cardiorenal medicine. 2024;14(1):45-57. DOI:10.1159/000535133 2024
Low Lean Tissue Index and Muscle Strength Combined with High Fat Tissue Index Are Associated with Cardiovascular Disease-Related Hospitalisation in Patients on Haemodialysis [0.03%]
低肌肉瘦体重指数和握力结合高脂肪组织指数与透析患者心血管相关住院的关系
Maolu Tian,Qin Lan,Jing Yuan et al.
Maolu Tian et al.
Introduction: The combined clinical impact of muscle mass, muscle function, and adipose mass on hospitalisation events, especially those that have exact causes, such as cardiovascular diseases (CVDs), had been rarely stud...
Observational Study
Cardiorenal medicine. 2023;13(1):363-371. DOI:10.1159/000534399 2023
Association of Chronic Kidney Disease with Cardiovascular Disease in Cancer Patients: A Cross-Sectional Study [0.03%]
癌症患者慢性肾脏病与心血管疾病关系的横断面研究
An-Bang Liu,Dan Zhang,Ting-Ting Meng et al.
An-Bang Liu et al.
Introduction: Due to the cardiotoxicity of cancer treatment and traditional risk factors for cardiovascular disease (CVD) such as obesity, diabetes, dyslipidemia, and hypertension, cancer patients are at higher risk of de...
Mild Renal Function Impairment and Long-Term Outcomes in Patients with Three-Vessel Coronary Artery Disease: A Cohort Study [0.03%]
肾功能轻度受损的三支冠状动脉疾病患者的长期预后：队列研究
Guyu Zeng,Deshan Yuan,Peizhi Wang et al.
Guyu Zeng et al.
Introduction: Limited data are available on the long-term impact of mild renal dysfunction (estimated glomerular filtration rate [eGFR] 60-89 mL/min/1.73 m2) in patients with three-vessel coronary disease (3VD). ...
Key Considerations regarding the Renal Risks of Iodinated Contrast Media: The Nephrologist's Role [0.03%]
碘化造影剂的肾风险相关要点：肾脏病专家的作用
Ravindra Mehta,David Sorbo,Federico Ronco et al.
Ravindra Mehta et al.
Background: The administration of iodinated contrast medium during diagnostic and therapeutic procedures has always been associated with the fear of causing acute kidney injury (AKI) or an exacerbation of chronic kidney d...
Volume Removal in Heart Failure: Current Concepts and a Look into the Future [0.03%]
心力衰竭中的容积去除：当前概念和未来展望
Adam Whaley-Connell,Claudio Ronco,Camila Manrique-Acevedo
Adam Whaley-Connell
Etelcalcetide Inhibits the Progression of Left Atrial Volume Index Compared to Alfacalcidol in Hemodialysis Patients [0.03%]
与阿尔法骨化醇相比，艾特司特卡肽可抑制透析患者的左心房容积指数的进展
Katharina Dörr,Roman Reindl-Schwaighofer,Matthias Lorenz et al.
Katharina Dörr et al.
Introduction: Increased left atrial (LA) size is a risk factor for cardiovascular events and all-cause mortality. It is closely related to left ventricular hypertrophy and chronic volume overload, both of which are common...
Randomized Controlled Trial
Cardiorenal medicine. 2023;13(1):332-341. DOI:10.1159/000533899 2023
The Worsening Renal Perfusion Index Predicts the Prognoses of Heart Failure Patients Treated with Sacubitril/Valsartan [0.03%]
肾灌注指数恶化可预测沙库必曲/缬沙坦治疗心力衰竭患者的预后
Wan-Tseng Hsu,Yu-Yang Cheng,Tsun-Yu Yang et al.
Wan-Tseng Hsu et al.
Introduction: Sacubitril/valsartan (S/V) reduces all-cause mortality in patients with heart failure with reduced ejection fraction (HFrEF), but it may decline their estimated glomerular filtration rates (eGFR). In additio...